UNITED LAB (03933) announced that its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has obtained implied clinical trial approval from the National Medical Products Administration for its self-developed Class 1 innovative drug, UBT38006 injection, with the acceptance number CXSL2600257. UBT38006 injection is a novel long-acting weekly insulin formulation with a unique molecular structure. The drug exerts its glucose-lowering effect by specifically binding to the human insulin receptor. Compared to existing insulin products, the most significant advantage of UBT38006 lies in its unique molecular design, which enables reversible binding to human albumin, significantly extending the drug's half-life. Based on preclinical animal data, it is estimated that a once-weekly dosing regimen can be achieved in humans. The development of UBT38006 is expected to greatly improve medication adherence among diabetic patients, reduce the treatment burden associated with frequent injections, and enhance their quality of life. This approval marks another important innovation for the company in the field of diabetes treatment. Moving forward, the company will continue to focus on the research and development of new products, with an emphasis on enhancing its competitiveness and creativity in the biopharmaceutical industry. It will deepen its efforts in the chronic disease treatment sector, aiming to serve clinical needs and benefit patients with higher-quality products and a more comprehensive pipeline, which is anticipated to generate greater returns for the company and its shareholders.
Comments